Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with certain types of aggressive B-cell lymphoma (including Diffuse Large B Cell Lymphoma and related high-grade B-cell lymphomas, including those that have transformed from a lower-grade lymphoma) on or after 1st January 2019
- People whose lymphoma has a specific genetic change in a gene called MYC, as detected by a specialised laboratory test called FISH
- People for whom certain laboratory protein marker tests (CD10, Bcl6, MUM1, Bcl2, Myc, and Ki67) have already been performed on their lymphoma tissue
- People who received treatment intended to cure their lymphoma (such as R-CHOP, R DA-EPOCH, or intensive chemotherapy similar to Burkitt lymphoma treatment) as their first course of treatment
- People for whom a preserved tissue sample (called an FFPE block) from their lymphoma biopsy is available and is of sufficient size and quality for further laboratory testing
- People aged between 18 and 79 years
Who may not be able to join:
- People whose lymphoma originated in the brain or spinal cord, or people diagnosed with plasmablastic lymphoma, Burkitt's lymphoma, or primary mediastinal B-cell lymphoma
- People who received treatment aimed at managing symptoms rather than curing the disease (palliative treatment)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Luisa Lorenzi, MD, SC Anatomia Patologica - ASST Spedali Civili di Brescia
Phone: +390131033153
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate the histopathological, genetic, clinical characteristics and outcome of patients with DLBCL or HGBCL with MYC rearrangements or GCN (alone or in association with BCL2 and BCL6) treated with curative intent therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.